Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
MCRB Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Seres Therapeutics, Inc.NASDAQ: MCRB
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit remains negative
Q1 FY2026 gross profit was -$423K, compared with -$3.53M a year earlier. Trailing-twelve-month gross profit was -$240K.
Context
- Gross profit amounted to 423.8% of revenue in FY2025.
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly gross profit holds near -$423K or moves back toward the trailing-twelve-month quarterly average of -$60K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (3.34M) USD
- Year-over-year change
- +5.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.34M) | +5.3% |
| FY2024 | 2024-12-31 | (3.53M) | +81.7% |
| FY2023 | 2023-12-31 | (19.34M) | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 144.93M | — |
Gross Profit vs competitors
How MCRB compares with its peers on the latest reported figures
- MCRB's LTM Mar 2026 gross profit of -$240K is the 8th highest of the 9 companies compared; the peer median is -$11.74K.
- Its year-over-year change of +97.6% is the 2nd highest of 7, against a peer median of +31.2%.
- Gross profit amounts to 20.9% of revenue for MCRB, versus a peer median of 49.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $54.77M | +162.7% | +7.1% | 100.0% | |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $5.95M | +1.3% | -29.1% | 49.6% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | -$23.47K | +63.1% | — | — | |
| LTM Mar 2026 | -$46K | -4.5% | — | — | |
| LTM Mar 2026 | -$129K | — | — | — | |
| LTM Mar 2026 | -$240K | +97.6% | — | 20.9% | |
| LTM Mar 2026 | -$2.24M | -69.6% | -81.5% | — | |
| Peer median (excluding MCRB) | -$11.74K | +31.2% | -11.0% | 49.6% | |
Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 144.93M | 0 | 0 | 0 | 789K |
| Cost of Revenue | 0 | 0 | 19.34M | 3.53M | 4.13M |
| Gross Profit | 144.93M | 0 | (19.34M) | (3.53M) | (3.34M) |
| Gross Margin | 100.0% | — | — | — | -423.8% |
| Research & Development | 141.89M | 109.65M | 117.6M | 64.6M | 49.06M |
| Selling, General & Admin | 69.26M | 70.26M | 77.5M | 53.18M | 39.16M |
| Operating Expenses | 209.42M | 179.91M | 175.76M | 117.78M | 90.63M |
| Depreciation & Amortization | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M |
| EBITDA | (56.72M) | (170.93M) | (181.42M) | (120.3M) | 9.83M |
| EBITDA Margin | -39.1% | — | — | — | 1245.8% |
| Operating Income | (64.49M) | (179.91M) | (195.1M) | (121.32M) | (93.97M) |
| Operating Margin | -44.5% | — | — | — | -11910.1% |
| Interest Income | 2.87M | 3.06M | 7.3M | 3.97M | 2.23M |
| Interest Expense | 2.91M | 6.02M | 13.18M | 0 | 0 |
| Other Income / Expenses | (1.09M) | (3.67M) | 4.97M | (4.46M) | 99.67M |
| Income Before Tax | (65.58M) | (183.58M) | (190.13M) | (125.77M) | 5.7M |
| Pre-Tax Margin | -45.2% | — | — | — | 721.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (65.58M) | (250.16M) | (113.72M) | (146.57M) | 5.7M |
| Net Margin | -45.2% | — | — | — | 721.9% |
| EPS (Basic) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| EPS (Diluted) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| Weighted Avg Shares | 4.59M | 5.4M | 6.4M | 7.77M | 8.86M |
| Weighted Avg Shares (Diluted) | 4.59M | 5.4M | 6.4M | 7.77M | 8.87M |
Seres Therapeutics, Inc.
NASDAQ:MCRB
Intrinsic Alpha fair value
Locked
Current Price
$5.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.